[go: up one dir, main page]

ZA200703888B - Anti-glypican 3 antibody having modified sugar chain - Google Patents

Anti-glypican 3 antibody having modified sugar chain

Info

Publication number
ZA200703888B
ZA200703888B ZA200703888A ZA200703888A ZA200703888B ZA 200703888 B ZA200703888 B ZA 200703888B ZA 200703888 A ZA200703888 A ZA 200703888A ZA 200703888 A ZA200703888 A ZA 200703888A ZA 200703888 B ZA200703888 B ZA 200703888B
Authority
ZA
South Africa
Prior art keywords
glypican
antibody
sugar chain
modified sugar
modified
Prior art date
Application number
ZA200703888A
Inventor
Nakano Kiyotaka
Sugimoto Masamichi
Tanaka Megumi
Sugo Izumi
Ishiguro Takahiro
Iijima Shigeyuki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ZA200703888B publication Critical patent/ZA200703888B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200703888A 2004-10-26 2007-05-14 Anti-glypican 3 antibody having modified sugar chain ZA200703888B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26

Publications (1)

Publication Number Publication Date
ZA200703888B true ZA200703888B (en) 2009-11-25

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703888A ZA200703888B (en) 2004-10-26 2007-05-14 Anti-glypican 3 antibody having modified sugar chain

Country Status (19)

Country Link
US (2) US7867734B2 (en)
EP (1) EP1816140A4 (en)
JP (1) JP4794457B2 (en)
KR (1) KR101296931B1 (en)
CN (1) CN101068836B (en)
AU (1) AU2005297772B2 (en)
BR (1) BRPI0518279A2 (en)
CA (1) CA2585196C (en)
CR (1) CR9151A (en)
IL (1) IL182662A (en)
MA (1) MA29025B1 (en)
MX (1) MX2007004593A (en)
NO (1) NO20072366L (en)
NZ (1) NZ554940A (en)
RU (1) RU2451030C2 (en)
TW (1) TWI468514B (en)
UA (1) UA93488C2 (en)
WO (1) WO2006046751A1 (en)
ZA (1) ZA200703888B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
US7863042B2 (en) * 2003-06-18 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
CN102702353A (en) * 2004-07-09 2012-10-03 中外制药株式会社 Anti-glypican 3 antibody
WO2006022407A1 (en) 2004-08-24 2006-03-02 Chugai Seiyaku Kabushiki Kaisha Adjuvant therapy with the use of anti-glypican 3 antibody
UA93488C2 (en) 2004-10-26 2011-02-25 Чугаі Сейяку Кабусікі Кайся Anti-glypican 3 antibody having modified sugar chain
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2584043A3 (en) * 2007-09-28 2013-10-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having improved kinetics in plasma
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
US8583781B2 (en) 2009-01-28 2013-11-12 Headwater Partners I Llc Simplified service network architecture
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
US12452377B2 (en) 2009-01-28 2025-10-21 Headwater Research Llc Service design center for device assisted services
US12166596B2 (en) 2009-01-28 2024-12-10 Disney Enterprises, Inc. Device-assisted services for protecting network capacity
US12543031B2 (en) 2009-01-28 2026-02-03 Headwater Research Llc Adapting network policies based on device service processor configuration
US11985155B2 (en) 2009-01-28 2024-05-14 Headwater Research Llc Communications device with secure data path processing agents
US12389218B2 (en) 2009-01-28 2025-08-12 Headwater Research Llc Service selection set publishing to device agent with on-device service selection
CN110038135B (en) 2011-03-17 2021-03-05 伯明翰大学 redirected immunotherapy
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
RU2688486C2 (en) * 2014-01-16 2019-05-21 Калиста, Инк. Microorganisms for high production of amino acids and related methods
KR102409014B1 (en) 2014-05-08 2022-06-14 추가이 세이야쿠 가부시키가이샤 Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
EP3318879B1 (en) 2015-07-01 2020-10-21 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective
BR112018002386A8 (en) * 2015-08-03 2022-10-18 Carsgen Therapeutics Ltd ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
KR101796688B1 (en) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 Novel Antibody Against Glypican 3, and Pharmaceuitical Composition Comprising the Same
BR112018015259A2 (en) 2016-01-27 2018-12-18 Medimmune Llc Methods for preparing antibodies with a defined glycosylation standard
EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
JP7125347B2 (en) 2016-08-22 2022-08-24 中外製薬株式会社 Genetically Modified Non-Human Animals Expressing Human GPC3 Polypeptides
CN106591371A (en) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 CD16A/GPC3 double-antibody lentivirus expression vector, and construction method and application thereof
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
BR112021006254A2 (en) 2018-10-01 2021-07-27 Adicet Bio, Inc. compositions and methods relating to engineered and unengineered t¿d cells for the treatment of solid tumors
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
CN113811331A (en) * 2019-05-24 2021-12-17 安立玺荣生医(香港)有限公司 anti-CSF 1R antibody, IL10 fusion protein and application thereof
KR20220017430A (en) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 Antibody Cleavage Site Binding Molecules
KR20220155588A (en) * 2020-03-18 2022-11-23 주식회사 유틸렉스 GPC3 CAR-T cell compositions and methods of making and using the same
US20240301085A1 (en) * 2021-02-10 2024-09-12 Simcere Zaiming Pharmaceutical Co., Ltd. Humanized gpc3 antibody and application thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (en) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd Ultrasonic inspection device
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (en) 1991-05-10 1992-11-24 Toshiba Corp Ultrasonic diagnosing device
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
RU2177805C2 (en) * 1997-02-12 2002-01-10 Чугаи Сейяку Кабусики Кайся Agent used in treatment of lymphatic tissue tumors
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
KR100473836B1 (en) * 1997-10-03 2005-03-07 츄가이 세이야꾸 가부시키가이샤 Natural humanized antibody
JPH11118775A (en) 1997-10-09 1999-04-30 Canon Inc Ultrasonic inspection equipment
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1176195T3 (en) 1999-04-09 2013-06-24 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
JP3606132B2 (en) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 Ultrasonic flaw detection method and apparatus
JP2002048867A (en) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd Acoustic survey device
DE60128817T2 (en) 2000-09-12 2008-02-07 Union Carbide Chemicals & Plastics Technology Corp., Danbury POLYMERIC MIXTURES CONTAINING ETHYLENE OXIDE COPOLYMERS
EA013224B1 (en) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Cells producing antibody compositions
JP4336051B2 (en) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ Wireless communication terminal, calling restriction method and program
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US20040236080A1 (en) * 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
WO2003011878A2 (en) * 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100559808B1 (en) * 2001-11-14 2006-03-15 가부시끼가이샤 도시바 Inspection device and ultrasonograph
JP4087098B2 (en) 2001-11-14 2008-05-14 株式会社東芝 Ultrasonic inspection equipment
JP3961359B2 (en) 2002-07-18 2007-08-22 株式会社東芝 Ultrasonic imaging device
WO2003057881A1 (en) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
JPWO2003085119A1 (en) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
DE60326567D1 (en) * 2002-05-23 2009-04-23 Sunnybrook & Womens College DIAGNOSIS OF HEPATOCELLULAR CARCINOMA
JP4406607B2 (en) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 Peptide and pharmaceutical containing the same
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004022595A1 (en) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20080008710A1 (en) * 2003-09-04 2008-01-10 Hiroyuki Aburatani Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma
ITBO20040008U1 (en) 2004-02-03 2004-05-03 Tonazzi S R L MACHINE FOR FILLING AND CLOSING TUBES
CN102702353A (en) * 2004-07-09 2012-10-03 中外制药株式会社 Anti-glypican 3 antibody
DK1778359T3 (en) * 2004-08-08 2011-02-07 Eli Khayat Pharmaceutical compositions for the relief of oxcessive sugar levels in patients with diabetes
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc ANTAGONISTS OF INTEGRIN HAVING CYTOTOXIC ACTION WITH CELL MEDIATION DEPENDENT OF ENHANCED ANTIBODY
WO2006022407A1 (en) 2004-08-24 2006-03-02 Chugai Seiyaku Kabushiki Kaisha Adjuvant therapy with the use of anti-glypican 3 antibody
UA93488C2 (en) 2004-10-26 2011-02-25 Чугаі Сейяку Кабусікі Кайся Anti-glypican 3 antibody having modified sugar chain
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP3689912A1 (en) * 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
JP5619603B2 (en) * 2008-03-17 2014-11-05 国立大学法人宮崎大学 Method for detecting hepatoma cells using anti-glypican 3 antibody
CL2009000647A1 (en) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.

Also Published As

Publication number Publication date
US7867734B2 (en) 2011-01-11
RU2007119579A (en) 2008-12-10
UA93488C2 (en) 2011-02-25
AU2005297772B2 (en) 2011-06-23
NO20072366L (en) 2007-06-21
CA2585196A1 (en) 2006-05-04
KR20070070222A (en) 2007-07-03
CA2585196C (en) 2015-01-06
AU2005297772A1 (en) 2006-05-04
MA29025B1 (en) 2007-11-01
JP4794457B2 (en) 2011-10-19
IL182662A (en) 2014-09-30
JPWO2006046751A1 (en) 2008-05-22
TWI468514B (en) 2015-01-11
KR101296931B1 (en) 2013-08-14
NZ554940A (en) 2010-04-30
US20080124330A1 (en) 2008-05-29
RU2451030C2 (en) 2012-05-20
US20110033452A1 (en) 2011-02-10
HK1110335A1 (en) 2008-07-11
TW200621980A (en) 2006-07-01
BRPI0518279A2 (en) 2008-11-11
WO2006046751A1 (en) 2006-05-04
CN101068836B (en) 2013-08-14
CN101068836A (en) 2007-11-07
EP1816140A4 (en) 2009-09-02
CR9151A (en) 2008-03-18
MX2007004593A (en) 2007-06-22
EP1816140A1 (en) 2007-08-08
IL182662A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ZA200703888B (en) Anti-glypican 3 antibody having modified sugar chain
GB0228210D0 (en) Single chain antibodies
PT1599504E (en) Modified antibody
IL227753A0 (en) Modified antibody or antibody fragment
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
IL179672A0 (en) Anti-cd3 antibodies
IL175710A0 (en) Anti-mpl antibody
IL187316A0 (en) Anti-interleukin 2 antibodies
IL187106A (en) Sclerostin-binding antibody
IL190472A0 (en) Anti-glypican-3 antibody
ZA200805850B (en) Anti-ILT7 antibody
IL185366A0 (en) Antibody
GB0420466D0 (en) Anti-glucan antibodies
GB2420392B (en) Silent chain
ZA200701952B (en) Anti-OX40L antibodies
GB0306618D0 (en) Antibody
GB2417997B (en) Link chain
EP1780221A4 (en) Anti-synoviolin antibody
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0417434D0 (en) Adaptable necklace
GB0421192D0 (en) Torque-chain combination necklace
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies